Patents
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
03/2004
03/02/2004US6699494 Side effect reduction
03/02/2004US6699493 Performing the transplant, and implanting in the eye a biodegradable drug delivery system comprising an immunosuppressant and a biodegradable polymer
03/02/2004US6699492 Quinolone carboxylic acid compositions and related methods of treatment
03/02/2004US6699491 Method for modulating glutamate and/or aspartate release in a central nervous system locus
03/02/2004US6699490 Parenteral release into the circulatory system of a cow somatotropin using a given dosage and concentration; free of absorption modifying agents, which can cause tissue irritation at the injection site
03/02/2004US6699467 As carriers for delivering active agents such as peptides, drugs by administration, such as oral, subcutaneous, sublingual, and intranasal administration
03/02/2004US6699461 UV-photostabilized sunscreen compositions comprising dibenzoylmethane/benzophenone compounds
03/02/2004US6699315 A hardenable propylene glycol alginate (pga) film-former and a surfactant in an aqueous solution of low viscosity; prompt release for drug and veterinary solid dosage forms, candy, seeds, animal feed, fertilizers, pesticides and foods
03/02/2004US6699218 Transcutaneous delivery means
03/02/2004US6698162 Methods of producing a terminally sterilized topical patch preparation
03/02/2004CA2232879C Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
03/02/2004CA2196906C Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
03/02/2004CA2105836C Bioerodible contraceptive suppository
02/2004
02/26/2004WO2004016720A2 Coated polyunsaturated fatty acid-containing particles and coated liquid pharmaceutical-containing particles
02/26/2004WO2004016551A1 Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate
02/26/2004WO2004016303A1 Threaded syringe with quick stop
02/26/2004WO2004016298A1 Microarray drug delivery coatings
02/26/2004WO2004016289A1 Topical anhydrous and ethanol-free ascomycin compositions
02/26/2004WO2004016286A2 Pharmaceutical anti-tnf-alpha antibody formulation
02/26/2004WO2004016275A1 Separate type medical material
02/26/2004WO2004016262A1 Amino acid-containing chewable
02/26/2004WO2004016252A1 Non-animal product containing veterinary formulations
02/26/2004WO2004016251A1 Sustained release pharmaceutical composition of a cephalosporin antibiotic
02/26/2004WO2004016250A1 Sustained release pharmaceutical composition of a cephalosporin antibiotic
02/26/2004WO2004016249A1 Extended release matrix tablets
02/26/2004WO2004016248A2 Galenic formulation for colon targeted delivery of active principles
02/26/2004WO2004016247A1 Process for coating a pharmaceutical particle
02/26/2004WO2004016246A1 Cannabinoid liquid formulations for mucosal amdinistration
02/26/2004WO2004016245A1 Optimal volume of intra-vaginal semisolid dosage forms for treating vaginal infections
02/26/2004WO2004016244A2 Pharmaceutical compositions for buccal delivery of pain relief medications
02/26/2004WO2004016243A2 Methods of administering and enhancing absorption of pharmaceutical agents
02/26/2004WO2004016242A2 A process for manufacture of stable oral multiple units pharamceutical composition containing benzimidazoles
02/26/2004WO2004016241A1 Antigenic compositions
02/26/2004WO2004016239A1 Topical formulation for prevention and treatment of acne
02/26/2004WO2004016238A1 Antiaging composition
02/26/2004WO2004016221A2 Sulfonamides as potassium channel blockers
02/26/2004WO2004006891A3 Delivery system for pharmaceutical agents
02/26/2004WO2004003188A3 Stabilization of granules
02/26/2004WO2004002423A3 Cartilage enhancing food supplements with sucralose and methods of preparing the same
02/26/2004WO2004000034A3 Anthelmintic oral homogeneous veterinary pastes
02/26/2004WO2003103624B1 Method and composition for improving sensory characteristics of semisolid predominantly anhydrous
02/26/2004WO2003099203A3 Enteric coated caffeine tablet
02/26/2004WO2003096991A3 Amelioration of the development of cataracts and other opthalmic diseases
02/26/2004WO2003096973A3 A direct cellular energy delivery system
02/26/2004WO2003091387A9 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands
02/26/2004WO2003090712A3 Compositions for treating hyperemia
02/26/2004WO2003090692A3 Make-up applicator with led light source
02/26/2004WO2003090684A3 Polymer compositions containing a macrocyclic triene compound
02/26/2004WO2003088985A3 Use of compositions containing petasites for treating diseases
02/26/2004WO2003087327A3 Preservation of bioactive materials by freeze dried foam
02/26/2004WO2003082209A3 Cochleates made with purified soy phosphatidylserine
02/26/2004WO2003078874A3 Coated microfluidic delivery system
02/26/2004WO2003075830A3 Oral controlled drug delivery system containing carbamazepine
02/26/2004WO2003070155A3 Orally administrable pharmaceutical formulation
02/26/2004WO2003068805A3 Formulation strategies in stabilizing peptides in organic solvents and in dried states
02/26/2004WO2003059197A3 The use of sulfonated compounds as a barrier contraceptive
02/26/2004WO2003053403A3 Pharmaceutical suspension for oral administration
02/26/2004WO2003043586A9 Compositions for sustained action product delivery
02/26/2004WO2003039464A3 Antimuscarinic aerosol
02/26/2004WO2003039436A3 Pharmaceutical compositions containing oxybutynin
02/26/2004WO2003034991A3 Taste masking spill-resistant formulation
02/26/2004WO2003034979A3 Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
02/26/2004WO2003032915A3 Viral inhibition by n-docosanol
02/26/2004WO2003026614A9 Dosage form containing a confectionery composition
02/26/2004WO2003007733A8 Protein-containing foodstuff comprising a cross-linking enzyme and a hydrocolloid
02/26/2004WO2003000232A3 Method for preparation of vesicles loaded with immunostimulator y oligodeoxynucleotides
02/26/2004WO2002103014A3 Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells
02/26/2004WO2002102355A3 Two part hard shell capsule made of poly (1,4-alpha-d-glucan)and starch
02/26/2004WO2002078608A3 A simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome or polyplex for systemic administration of a therapeutic or diagnostic agent
02/26/2004WO2002072636A8 Crystals of whole antibodies and fragments thereof and methods for making and using them
02/26/2004WO2002057211A8 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use
02/26/2004WO2002055067A3 Fumaric acid derivatives as nf-kappab inhibitors
02/26/2004WO2002051237A3 Helicobacter proteins, nucleic acids and uses thereof
02/26/2004WO2002041910A8 Methods and compositions for the treatment of diseases of the eye
02/26/2004WO2002038775A3 METHODS FOR PRODUCING AND PURIFYING RECOMBINANT α-L-IDURONIDASE
02/26/2004US20040039376 Sustained delivery of an active agent using an implantable system
02/26/2004US20040039356 Compositions for external preparations
02/26/2004US20040039204 Compositions of n-(methylethaylaminocarbonyl)-4-(-3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosacccharides
02/26/2004US20040039171 Method of forming polypeptide particles
02/26/2004US20040039065 Autonomic nerve regulating agent
02/26/2004US20040039057 Putrescine, spermine, spermidine or cadaverine with urea or lidocaine
02/26/2004US20040039050 Formulating phenanthro(1,2-b)-furan compound for eliminating hyperammonemia in the brain tissue for treating early stage Alzheimer's disease
02/26/2004US20040039036 Oral solution containing famotidine and edetic acid or a salt
02/26/2004US20040039022 Storage stable mixtures of (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol, water, buffers and chelate compounds used as neuroprotectants
02/26/2004US20040039021 Pharmaceutical anti-inflammatory aerosol formulation
02/26/2004US20040039020 Novel pharmaceutical formulation suitable for nebulisation
02/26/2004US20040039011 Administering anticholinergic or bronchodilator agents such as tiotropium bromide for prophylaxis of respiratory system disorders
02/26/2004US20040038984 Composition for male & female sexual arousal
02/26/2004US20040038957 Anti-malarial activity
02/26/2004US20040038953 Medical combination comprising salmeterol and budesonide
02/26/2004US20040038952 Combination of a bile acid and a bioflavonoid; also for treating eye disorders and premenstrual symptoms.
02/26/2004US20040038951 Organic compounds
02/26/2004US20040038948 Promoting healing through enhanced regeneration of hard or soft tissue contact with an anti-inflammatory agent; useful in treating periodontal diseases and in orthopedic applications.
02/26/2004US20040038937 Method and device for avoiding alteration of a substance having biological activities
02/26/2004US20040038936 Pharmaceutical composition containing viscoelastic substance and medication
02/26/2004US20040038935 Delivery of a therapeutic agent in a formulation for reduced toxicity
02/26/2004US20040038927 Methods of decreasing or preventing pain using spicamycin derivaties
02/26/2004US20040038916 Delivery of a therapeutic agent in a formulation for reduced toxicity
02/26/2004US20040038903 Gonadotropin releasing hormone antagonists in gel-forming concentration
02/26/2004US20040038893 Prevention and reduction of blood loss